← brief for 2026-09-08 · Slowing decline

Finerenone-Based Dual Versus Triple Therapy with SGLT2 Inhibitors and GLP-1 Receptor Agonists in Type 2 Diabetes Mellitus Associated Chronic Kidney Disease: A Retrospective Cohort Study.

Article C Peer reviewed Observational

Key takeaways

Doctors reviewed the records of adults whose kidney disease came from type 2 diabetes to compare two drug combinations. One group took finerenone plus an SGLT2 inhibitor, and the other added a third drug, a GLP-1 receptor agonist. After 6 months the team measured kidney filtering rate (eGFR), protein in the urine (the albumin-to-creatinine ratio), and side effects. This was a look back at past records, not a randomized trial, so it shows a link between the drug combinations and the results, not proof that one combination caused better kidneys.

Who did this work

Khogalee M · Mohamed S · Otim ME · Basher M · Mumtaz M · Thaslim S · El Houni A

Source

Article · PubMed, the drug frontier · 2026 Sep 8
https://pubmed.ncbi.nlm.nih.gov/42711176/